Skip to content

Ketamine: all studies

Page 100 of 448: studies 991 to 1,000 of 4,475, newest first. Back to the ketamine overview

Research

Effect of Low-Dose Ketamine Infusion in the Intensive Care Unit on Postoperative Opioid Consumption and Traumatic Memories After Hospital Discharge: A Randomized Controlled Trial.

Anesthesia & Analgesia February 5, 2025 Nuanprae Kitisin, Nattaya Raykateeraroj, Nattachai Hemtanon et al. 11 citations

Low-dose ketamine may have an opioid-sparing effect in critically ill patients but may also predispose them to traumatic memories. We evaluated the effects of low-dose ketamine infusion in the intensive care unit (ICU) on fentanyl consumption and traumatic memories after hospital discharge. This randomized, double-blind, controlled trial was conducted at a university-based surgical ICU. 118...

DOI: 10.1213/ANE.0000000000007419 (opens in new tab) Full text (opens in new tab) Ketamine Pain management Post-operative care Opioid reduction +1

Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.

The International Journal of Neuropsychopharmacology February 4, 2025 Yingliang Dai, Ben J. Harrison, Christopher G. Davey et al. 6 citations

Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown effectiveness as a rapidly acting treatment for depression. Although advances have been made in understanding ketamine's antidepressant pharmacological and molecular mechanisms of action, the large-scale neurocognitive mechanisms driving its therapeutic effects are less clearly understood. To help provide such a framework,...

DOI: 10.1093/ijnp/pyaf010 (opens in new tab) Full text (opens in new tab) Neurocognitive Depression/mental-health/mood-disorders Ketamine/psychopharmacology/antidepressants Neuroscience/neurobiology/brain-research

MAGNETIC SUBCORTICAL SUSCEPTIBILITY IS ASSOCIATED WITH THE TREATMENT OUTCOME OF REPEATED KETAMINE INFUSION FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

The International Journal of Neuropsychopharmacology February 1, 2025 Kengo Yonezawa, Hideaki Tani, Shuhei Shibukawa et al.

Abstract Background Whereas ketamine has displayed robust antidepressant effects in treatment-resistant depression (TRD) (Han et al., 2016), only 30-40% of patients with TRD respond to ketamine therapy (Wilkinson et al., 2018; Sakurai et al., 2020). Several postmortem studies have shown decreased myelination in patients with depression (Hamidi, Drevets and Price, 2004; Altshuler et al., 2010),...

ASSOCIATION OF NEUROFILAMENT LIGHT CHAIN WITH THE ANTIDEPRESSANT EFFECTS OF LOW-DOSE KETAMINE INFUSION AMONG PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

The International Journal of Neuropsychopharmacology February 1, 2025 Hui-Ju Wu, *Mu-Hong Chen, Wei-Chen Lin

Abstract Background The role of neurofilament light chain (NFL) in treatment-resistant depression (TRD) is unclear. Whether baseline NFL concentrations are associated with the antidepressant effects of low- dose ketamine infusion has not been determined. Methods The NFL concentrations of 71 patients with TRD and 17 healthy controls were assessed. Patients with TRD were randomly administered a...

Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.

Clinical Pharmacology & Therapeutics February 1, 2025 Ksenia A Vekhova, Eugenia D Namiot, Jörgen Jonsson et al. 43 citations

Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)-ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment-resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of clinical trials. This analysis provides a...

DOI: 10.1002/cpt.3478 (opens in new tab) Full text (opens in new tab) Esketamine. Drug. Clinical trials. Research. +8

Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.

Biological Psychiatry February 1, 2025 Cassiano Ricardo Alves Faria Diniz, Ana Paula Crestani, Plinio Cabrera Casarotto et al. 15 citations

Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (brain-derived neurotrophic factor). Although neurotrophins such as BDNF can bind to p75NTR (p75 neurotrophin receptor), their precursors are the high-affinity p75NTR ligands. While part of an unrelated receptor family capable of inducing completely...

How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.

International Journal of Mental Health Nursing February 1, 2025 Melanie Trimmel, Antonia Renner, Alexander Kaltenboeck 4 citations

Ketamine treatment has shown promising effects for different mental disorders. Yet, little is known on how people who receive ketamine for a psychiatric problem subjectively experience undergoing this intervention. We conducted a systematic literature search to identify relevant qualitative research on the first-person experience of undergoing ketamine treatment in a psychiatric context. 24...

Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review.

Journal of Affective Disorders February 1, 2025 Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al. 4 citations

Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...

Acute effects of esketamine on hypoxic ventilatory response, haemodynamics, and brain function in healthy volunteers.

British Journal of Anaesthesia February 1, 2025 Simone C Jansen, Monique van Velzen, Elise Sarton et al. 11 citations

The acute hypoxic ventilatory response is a critical chemoreflex originating at the carotid bodies. This study investigates the impact of low-dose i.v. esketamine on the ventilatory response to 20 min of isocapnic hypoxia to test the hypothesis that esketamine does not affect hypoxic ventilation. In this open-label study, 18 healthy subjects received a 3-h escalating i.v. infusion of...

DOI: 10.1016/j.bja.2024.08.040 (opens in new tab) Full text (opens in new tab) Esketamine Haemodynamics Hypoxic ventilatory response Anesthesia +4

Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.

European Neuropsychopharmacology February 1, 2025 Danica E. Johnson, Nelson B Rodrigues, Sydney Weisz et al.

Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients...